Virgen de la Arrixaca Hospital Achieves European Recognition for Theranostics in Cancer Treatment
Virgen de la Arrixaca Hospital in Murcia renews its European Center of Excellence recognition for advanced cancer theranostics.
Key Points
- • Renewed European accreditation as a Center of Excellence for Theranostics.
- • Hospital is the only facility in the Region providing advanced radioligand therapies.
- • Expanded range of treatments, including Renio-188 and actinium for various cancers.
- • Theranostics improves patient outcomes by combining therapy and diagnosis.
The Virgen de la Arrixaca Hospital in Murcia has renewed its status as a Center of Excellence for Theranostics, according to a recent announcement. This accreditation, granted by the European Association of Nuclear Medicine, solidifies the hospital's standing in the specialized field that merges therapy and diagnosis for cancer treatment, making it a leader in innovative medical therapies in Spain.
Theranostics, a field that utilizes radioactive isotopes to target cancer cells directly, allows for more precise treatment strategies. As the only hospital in the Region of Murcia certified for these advanced radioligand therapies, Virgen de la Arrixaca is expanding its portfolio of treatment options. The new certification includes treatments using Renio-188 and actinium which will benefit patients with various types of cancers, particularly skin and prostate cancers.
Hospital officials noted that this renewed accreditation not only affirms their commitment to high-quality care but also acknowledges their advancements in metabolic therapies that use radiopharmaceuticals designed to deliver targeted therapeutic doses. Health Minister Juan José Pedreño emphasized that this achievement highlights the excellence of the regional healthcare services and the dedication of healthcare professionals within the system.
In addition to this certification, the hospital has also been recognized as a PET-CT Center of Excellence, ensuring that it meets standardized performance criteria across multicenter trials. The combination of diagnostic and therapeutic approaches in theranostics has been shown to significantly improve patient outcomes, including increased overall survival rates and enhanced quality of life for patients with specific tumor types.
Among established therapies, the hospital is already utilizing Renio-86 for arthritis and Samario-153 for managing bone pain associated with metastases, with newer options anticipated to further elevate treatment possibilities for patients. With these developments, theranostics is expected to play an increasingly vital role in the future of cancer care at Virgen de la Arrixaca.